Distinguishing among incretin-based therapies. Introduction

The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of family practice 2010-09, Vol.59 (9 Suppl 1), p.S3-S4
Hauptverfasser:	Campbell, R Keith, Cobble, Michael E, Reid, Timothy S, Shomali, Mansur E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - analogs & derivatives Adamantane - therapeutic use Blood Glucose - drug effects Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Dipeptides - therapeutic use Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Drug Administration Schedule Gastric Inhibitory Polypeptide - metabolism Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide 1 - therapeutic use Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Incretins - pharmacokinetics Incretins - pharmacology Incretins - therapeutic use Insulin - metabolism Insulin Resistance Insulin-Secreting Cells - physiology Liraglutide Metformin - therapeutic use Peptides - therapeutic use Pyrazines - therapeutic use Receptors, Glucagon Sitagliptin Phosphate Triazoles - therapeutic use Venoms - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of
ISSN:	1533-7294